ENTL has been the topic of a number of other research reports. ValuEngine lowered shares of Entellus Medical from a sell rating to a strong sell rating in a research note on Tuesday, May 23rd. BidaskClub lowered shares of Entellus Medical from a strong-buy rating to a buy rating in a research note on Saturday, July 8th. Zacks Investment Research upgraded shares of Entellus Medical from a sell rating to a hold rating in a research note on Tuesday, April 25th. Canaccord Genuity lowered shares of Entellus Medical from a buy rating to a hold rating and dropped their price target for the stock from $22.00 to $18.00 in a research note on Thursday, May 4th. Finally, William Blair restated an outperform rating on shares of Entellus Medical in a research note on Wednesday, May 10th. Three analysts have rated the stock with a sell rating, two have given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Entellus Medical has an average rating of Hold and a consensus target price of $21.83.
Shares of Entellus Medical (ENTL) traded down 4.00% during midday trading on Wednesday, reaching $17.03. 288,258 shares of the company’s stock traded hands. Entellus Medical has a 1-year low of $11.47 and a 1-year high of $22.63. The firm’s 50-day moving average price is $15.43 and its 200 day moving average price is $15.18. The stock’s market capitalization is $373.23 million.
Entellus Medical (NASDAQ:ENTL) last posted its quarterly earnings data on Wednesday, May 3rd. The medical technology company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.04. The company had revenue of $19.11 million for the quarter, compared to analyst estimates of $19.61 million. Entellus Medical had a negative net margin of 39.02% and a negative return on equity of 60.56%. The business’s quarterly revenue was up 13.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.37) earnings per share. On average, equities analysts predict that Entellus Medical will post ($1.35) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Entellus Medical, Inc. (ENTL) Rating Reiterated by Piper Jaffray Companies” was published by BBNS and is the property of of BBNS. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://baseballnewssource.com/markets/piper-jaffray-companies-reaffirms-buy-rating-for-entellus-medical-inc-entl-updated/1180164.html.
In related news, insider Robert S. White acquired 10,000 shares of Entellus Medical stock in a transaction that occurred on Monday, May 8th. The stock was acquired at an average price of $12.24 per share, with a total value of $122,400.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Brent Moen acquired 6,100 shares of Entellus Medical stock in a transaction that occurred on Monday, May 8th. The stock was bought at an average cost of $12.21 per share, with a total value of $74,481.00. The disclosure for this purchase can be found here. In the last three months, insiders have bought 17,700 shares of company stock valued at $216,625. Corporate insiders own 9.10% of the company’s stock.
A number of large investors have recently modified their holdings of ENTL. Frontier Capital Management Co. LLC acquired a new stake in shares of Entellus Medical during the first quarter worth $6,464,000. Kingdon Capital Management L.L.C. increased its stake in Entellus Medical by 79.6% in the first quarter. Kingdon Capital Management L.L.C. now owns 450,371 shares of the medical technology company’s stock valued at $6,215,000 after buying an additional 199,615 shares during the last quarter. Vanguard Group Inc. increased its stake in Entellus Medical by 77.8% in the first quarter. Vanguard Group Inc. now owns 424,823 shares of the medical technology company’s stock valued at $5,862,000 after buying an additional 185,833 shares during the last quarter. Cortina Asset Management LLC increased its stake in Entellus Medical by 22.6% in the first quarter. Cortina Asset Management LLC now owns 412,323 shares of the medical technology company’s stock valued at $5,690,000 after buying an additional 75,879 shares during the last quarter. Finally, William Blair Investment Management LLC increased its stake in Entellus Medical by 1,017.0% in the first quarter. William Blair Investment Management LLC now owns 390,334 shares of the medical technology company’s stock valued at $5,387,000 after buying an additional 355,388 shares during the last quarter. 75.79% of the stock is owned by institutional investors.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with our FREE daily email newsletter.